-

[616.12-005.4:616.13-004.6:616.127-089.168.1];616-008.9
-


2009 . . . , . .
. . . , .
(), , , , . . , [4, 7, 23]. (), .
, , - - [11, 13, 15, 21], . , ( , ) [2, 8, 12, 19, 20, 24], - . [12] » , . [5, 9, 17, 19] - . - , .
- .

61 - , 20042005 - » . . - . : , , ( 40 %), .
. 81 35 65 . - . . (). ( = 0,33) ( = -0,27), () ( = -0,27), ( = -0,35), ( = -0,49) ( = -0,51). , . .
: , , .
52 ( : , 30, 60 120 75 ).
L4L5 ( ).
( 12 ).
61 -. BioVendor» (). 315 /.
»- AccuBind Elisa» (). 0,79,0 /. HOMA (Homeostasis model assessment) : = , / * , / /22,5.
+ SD. . . , ( < 0,05), Bonferroni. < 0,05. . SPSS for Windows 13,0 .

61 35 65 , (52,4 ± 7,5) . : III (78 %) IV (14 %), 8 % . (4,8 ± 2,3) . - (67 %) . 56 (70 %) . 67 (83,8 %) . (12,0 ± 8,3) 53 (66 %) .
- 2004 2005 .
(72 88,7 %) .
31 (38,8 %) , 4 (5 %) ( -).
( = 61) () (28,6 ± 4,9) /2 (. 1). 66 % . (27 ) 25,0 29,9 /2, (27 ) 30,0 /2. I 24 ,
II 3. ( 25,0 /2) 26 (33 %). 20,0 /2.
1

, /
<1,76 (n=21) 1,76-2,2 (n=20) >2,2 (n=20)
, 47,0±6,9 55,0±6,9 56,5±7,6 0,000
, /2 29,6±4,0 29,1±4, 25,6±4,0 0,007
, 10,±11, 99,1±14,5 90,4+15,7 0,015
, 2 202,9±94,8 19,2±71,6 1,6±9,4 0,033
, , 130 2, , . (187,0 ± 90,6) 2. (67 %) 130 2. 33 % 130 2.
(5,60 ± 0,81) /, ( = 0,000) (. 2). (75 %) , , 50 % - 5,06,2 /. 21 (25 %) , 6,2 /, 20 (25 %) 5 /.
(1,90 ± 0,78) /, ( = 0,000) . (66 %)
2

I II III
, / 5,6±0,78 5,7±1,03 5,4±0,6 0,5
, /. 2,7±1,01 2,1±0,88 1,6±0,53 0,000
, / 3,6±0,65 3,9±0,89 3,8±0,57 0,48
/ 3,68±2,0 2,7±1,4 1,9±0,62 0,000
, 41 % 1,7 2,2 /, 25 % , 2,2 /, 28 (34 %) 1,7 /, 25 /2.
(3,8 ± 0,62) /, (0,89 ± 0,10) /.
2,30 ± 0,68, - ( 120 ) (47,8 ± 13,4) /.
- () . . McLaughin [16], . , (1,32 /), . 2,6 ± 1,5.
5 18 /. ( = 61) ( 1,9 /, Q25 1,6 ^75 2,5). , , . . . [1]. 1,9 4,1 /, 58 % .
, () -: I <1,76 / ( = 21),
II 1,762,2 / ( = 20),
III > 2,2 / ( = 20).
(. . 1). -
( = 0,33; = 0,001). . ( MONICA/KORA Augsburg, Health Professionals Follow-up Study), ( AtheroGene) [10, 15, 20, 21, 22]. , , , [24]
: (202,9 ± 94,8) 2 (I ), II ( 1,762,2 / ) (193,2 ± 71,6) 2 I , (III ) (133,6 ± 93,4) 2. ( = 0,27; = 0,046). ( = 0,606; p = 0,000) (r = 0,508; = 0,002). (R2 0,47; Adjusted R2 0,43; F 13,5; = 0,000; Standardized Coefficient Beta 0,421; = 0,004; 0,465; = 0,001). : = 103,049 + (/) 41,38 + (/) 41,93. -103,049 ( = 0,017).
, () (r = 0,27; = 0,008 r = 0,31; = 0,003). . (<1,76 /) (29,6 ± 4,0) /2 (103,3 ± 11,3) . British Regional Heart Study, (r = 0,21) [9, 12, 20].
/ . (<1,76 /)
I (2,70 ± 1,01) / / 3,68 ± 2,00.
, (r = 0,35; = 0,001), / (r = 0,30; = 0,004). , AtheroGene (r = 0,22) British Regional Heart Study (BRHS) (r = 0,25) [24, 13, 23]. - / .
- () >15 / [16] . . 120 , -IR , , 2,4 2,7. , . (III ) ( = 0,06). (I ) (16,8 ± 4,7) /. ( = 0,001). . I (2,95 ± 1,02).
2- ( ). , (. 3). III , 120 . I , 120 II III (7,1 ±
1,0) /.
, . (r = 0,40; = 0,01) (r = 0,41; = 0,012) .
3
-

I II III
, / 5,5±0,53 4,8±0,94 4,1±0,72 0,007
/ 120 , / 7,1±1,0 6,6±1,7 4,4±1,04 0,001
, / 16,8±4,7 14,5±11,8 7,1±2,7 0,048
/ 120 , / 78,1±15,8 65,2±14,6 14,2+12,5 0,001
- 2,95±1,02 2,3±0,82 1,59+0,58 0,023
. . [ 1 ], , - . 120 . (r = 0,49; = 0,003 r = 0,51; = 0,002). . (R2 0,381; Adjusted R2 0,341; F 9,25; = 0,001; Stardardized Coefficients Beta -0,385; p =
0,014; -0,387; p = 0,013).
: (/) = 4,78 120 (/) 0,252 (/) 0,439. 4,78 ( = 0,000). : /; 120 .
(r = 0,49; = 0,003). , (R2 = 0,24; = 0,003). . = 0,6 + (/) 0,96. 0,6 ( = 0,021).
, () , .
( = 0,51) ( = 0,48) (. . 2), , .
, . ,

. T . , T , ^ (r = -0,37; - 0,033), (r = -0,36; = 0,04), (r = -0,43; = 0,011) 20 ^ (r = -0,43; = 0,01). T ^ (r = -0,36; = 0,043), (r = -0,40; = 0,02) 120 ^ (r = -0,36; = 0,039). T , T ^ .
T , - : , , ^ T . , , , .

, . , - . . ,
, .
, - , .

1. . . : . . ... . . / T . . - ., 2009.
2. Cavusoglu E. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain / E. Cavusoglu,
C. Ruwende, V. Chopra, et al. // Eur. Heart J. - 2006. -Vol. 27. - P 2300-2309.
3. Costacou T. The prospective association between adiponectin and coronary artery disease among individuals with type diabetes. The Pittsburgh Epidemiology in Diabetes Complications Study / T. Costacou, J. C. Zgibor, R. W Evans, et al. // Diabetologia. - 2004. - Vol. 48. - P 4-48.
4. Efstathiou S. P. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke / S. P. Efstathiou,
D. I. Tsioulos, A. G. Tsiakou, et al. // Stroke. - 2005. -Vol. 36. - P 1915-1918.
5. Frystyk J. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men / J. Frystyk, C. Berne, L. Berglund, et al. // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92. - P. 571-576.
6. George J. Circulating adiponectin concentrations in patients with congestive heart failure / J. George, S. Patal, D. Wexler, et al. // Heart. - 2006. - Vol. 92. - 1420-1424.
7. Kadowaki T. Adiponectin and adiponectin receptors / T. Kadowaki, T. Yamauchi // Endocr. Rev. - 2005. -Vol. 26. - P 439-451.
8. Kanaya A. M. Serum adiponectin and coronary heart disease risk in older black and white Americans /
A. M. Kanaya, Fyr. C Wassel., E. Vittinghoff, et al. ; Health ABC Study // J. Clin. Endocrinol. Metab. - 2006. -Vol. 91. - P 5044-5050.
9. Kistorp C. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure / C. Kistorp, J. Faber, S. Galatius, et al. // Circulation. - 2005. -Vol. 112. - P. 1756-1762.
10. Koenig W. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany / W Koenig, N. Khuseyinova, J. Baumert, et al. // J. Am. Coll. Cardiol. - 2006. - Vol. 48. - P 1369-1377.
11. Kojima S. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction / S. Kojima, T. Funahashi,
F. Otsuka, et al. // Atherosclerosis. - 2007. - Vol. 194. -P 204-213 [CrossRef].
12. Laughlin G. A. Association of adiponectin with coronary heart disease and mortality / G. A. Laughlin,
E. Barrett-Connor, S. May, C. Langenberg // Am. J. Epidemiol. - 2007. - Vol. 165. - P 164-174.
13. LawlorD. A. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women / D. A. Lawlor, G. Davey Smith, S. Ebrahim, et al. // J. Clin. Endocrinol. Metab.
2005. - Vol. 90. - P. 5677-5683.
14. Lim S. Association of adiponectin and resistin with cardiovascular events in Korean patients with type
2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study / S. Lim, B. K. Koo, S. W. Cho, et al. // Atherosclerosis. 2008. Vol. 196. P. 398404.
15. Lindsay R. S. Adiponectin and coronary heart disease. The Strong Heart Study / R. S. Lindsay, H. E. Resnick, J. Zhu, et al. // Arterioscler. Thromb. Vasc. Biol. 2005.
- Vol. 25. - P. 1516.
16. McLaughlin T. Use of metabolic markers to identify overweight induviduals who are insulin resistant / T. McLaughlin et al. // Ann. Intern. Med. 2003. 139:132-137.
17. Menon V. Adiponectin and mortality in patients with chronic kidney disease / V. Menon, L. Li, X. Wang, et al. // J. Am. Soc. Nephrol. - 2006. - Vol. 7. - P. 2599-2606.
18. Nishizawa H. Androgens decrease plasma adiponectin,an insulin-sensitizing adipocyte-derived protein / H. Nishizawa, I. Shimomura, K. Kishida, et al. // Diabetes.
- 2002. - Vol. 51. - P. 2734274.
19. Pilz S. Adiponectin and mortality in patients undergoing coronary angiography / S. Pilz, H. Mangge,
B. Wellnitz, et al. // J. Clin. Endocrinol. Metab. 2006. Vol. 91. - P. 4277-4286.
20. Pischon T. Plasma adiponectin levels and risk of myocardial infarction in men / T. Pischon, C. Girman,
G. S. Hotamisligil, et al. // JAMA. 2004. Vol. 29 . P. 17301731.
21. Sattar N. Adiponectin and coronary heart disease: a prospective study and meta-analysis / N. Sattar, T. Pischon,
C. Girman, G. S. Hotamisligil, et al. // Circulation. - 2006.
- Vol. 4. - P. 623-629.
22. Schulze M. B. Adiponectin and future coronary heart disease events among men with type 2 diabetes / M. B. Schulze, I. Shai, E. B. Rimm, et al. // Diabetes. -
2006. - Vol. 54. - P. 534-539.
23. Szmitko P. E. Adiponectin and cardiovascular disease / P. E. Szmitko, H. Teoh, D. J. Stewart, S. Verma / Am. J. Physiol. Heart Circ. Physiol. - 2007. - Vol. 292. -P. H1655H1663.
24. Wolk R. Association between plasma adiponectin levels and unstable coronary syndromes / R. Wolk, P. Berger, R. J. Lennon, et al. // Eur. Heart J. 2007. Vol. 28. P. 292298.
25. Zoccali C. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease / C. Zoccali, F. Mallamaci, G. Tripepi et al. // J. Am. Soc. Nephrol. 2006. Vol. 13. P. 134141.
ADIPONECTIN AND HORMONAL-METABOLIC RISK FACTORS IN PATIENTS WITH CORONARY HEART DISEASE AFTER MYOCARDIAL REVASCULARIZATION SURGERY
T. V. Supryadkina, . . Mochalov
City Clinical Emergency Hospital 1 named after
E. . Volosevitch, Arkhangelsk
The purpose was to study interrelation between adiponectin levels and metabolic risk factors among patients with coronary heart disease (CHD), underwent coronary artery bypass(CAB). There were 81 patients, men aged 35-65 years (mean 52,4 ± 7,5 years). Concentration of adiponectin were measured using commercially available kits. The patients were devided into three groups according to adiponectin concentration (tertils). Was revealed statistically significant positive associations of adiponectin levels with age (r = 0,33) and an inverse associations with triglycerides (r = 0,35), BMI (r = 0,27),visceral fat area (r = 0,27), postprandial glucose (r = 0,49) and insulin levels (r = 0,51). Was established, that visceral fat area in aggregate with adiponectin level are independent predictors of postprandial insulin. level. Independent associations of adiponectin levels with metabolic parameters were revealed.
Key words: adiponectin, coronary heart disease, adiposis.
:
. . . . » .
E-mail: suprt@rambler.ru
24.09.2009 .